Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Cross-Sectional Evaluation of Surface Contamination with Antineoplastic Drugs in Canadian Health Care Centres.

Hilliquin D, Tanguay C, Gagné S, Caron NJ, Bussières JF.

Can J Hosp Pharm. 2019 Sep-Oct;72(5):377-384. Epub 2019 Oct 21.

2.

Evaluation of decontamination strategies for cyclophosphamide.

Soubieux A, Palamini M, Tanguay C, Bussières JF.

J Oncol Pharm Pract. 2020 Mar;26(2):413-422. doi: 10.1177/1078155219865931. Epub 2019 Aug 1.

PMID:
31370747
3.

Validity of criticism of Cochrane Review on closed-system drug-transfer devices.

Gurusamy KS, Ruotsalainen J, Verbeek J, Tanguay C, Best L, Lennan E, Korva M, Bussieres JF.

Am J Health Syst Pharm. 2019 Sep 1;76(17):1267-1269. doi: 10.1093/ajhp/zxz136. No abstract available.

PMID:
31340026
4.

Biological Monitoring of 4 Antineoplastic Drugs in Health Care Workers from 2 Adult Hospitals: A Pilot Study.

Chauchat L, Tanguay C, Therrien R, Dufour A, Gagné S, Caron NJ, Bussières JF.

Can J Hosp Pharm. 2019 Jan-Feb;72(1):56-59. Epub 2018 Feb 28. No abstract available.

5.

Investigational drug labeling variability.

Duhamel A, Thibault M, Lebel D, Bussières JF, Tanguay C.

Clin Trials. 2019 Apr;16(2):204-213. doi: 10.1177/1740774519828382. Epub 2019 Feb 3.

PMID:
30714394
6.

Surface contamination with ten antineoplastic drugs in 83 Canadian centers.

Chauchat L, Tanguay C, Caron NJ, Gagné S, Labrèche F, Bussières JF.

J Oncol Pharm Pract. 2019 Jul;25(5):1089-1098. doi: 10.1177/1078155218773862. Epub 2018 May 4.

PMID:
29726786
7.

Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff.

Gurusamy KS, Best LM, Tanguay C, Lennan E, Korva M, Bussières JF.

Cochrane Database Syst Rev. 2018 Mar 27;3:CD012860. doi: 10.1002/14651858.CD012860.pub2. Review.

8.

A response to the letter to the editor on Biomonitoring great, but do it the right way! Re: Poupeau et al. Pilot study of biological monitoring of four antineoplastic drugs among Canadian healthcare workers.

Tanguay C, Bussières JF.

J Oncol Pharm Pract. 2019 Jan;25(1):252-253. doi: 10.1177/1078155218761801. Epub 2018 Mar 20. No abstract available.

PMID:
29558839
9.

Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals.

Poupeau C, Tanguay C, Caron NJ, Bussières JF.

J Oncol Pharm Pract. 2018 Jan;24(1):9-17. doi: 10.1177/1078155216676632. Epub 2016 Oct 31.

PMID:
27799608
10.

The Effects of a Single Session of Music Therapy on the Agitated Behaviors of Patients Receiving Hospice Care.

Cadwalader A, Orellano S, Tanguay C, Roshan R.

J Palliat Med. 2016 Aug;19(8):870-3. doi: 10.1089/jpm.2015.0503. Epub 2016 Apr 26.

PMID:
27115462
11.

Pilot study of biological monitoring of four antineoplastic drugs among Canadian healthcare workers.

Poupeau C, Tanguay C, Plante C, Gagné S, Caron N, Bussières JF.

J Oncol Pharm Pract. 2017 Jul;23(5):323-332. doi: 10.1177/1078155216643860. Epub 2016 Apr 15.

PMID:
27084515
12.

Environmental Contamination with Cyclophosphamide, Ifosfamide, and Methotrexate: A Study of 51 Canadian Centres.

Janes A, Tanguay C, Caron NJ, Bussières JF.

Can J Hosp Pharm. 2015 Jul-Aug;68(4):279-89.

13.

[Review and analysis of the evidence on the role and the impact of pharmacists' activities: Development of an online tool].

Guérin A, Tanguay C, Lebel D, Bussières JF.

Ann Pharm Fr. 2015 May;73(3):229-38. doi: 10.1016/j.pharma.2014.09.004. Epub 2014 Nov 11. French.

PMID:
25934531
14.

[Characteristics of systematic reviews about the impact of pharmacists].

Tanguay C, Guérin A, Bussières JF.

Ann Pharm Fr. 2014 Nov;72(6):429-39. doi: 10.1016/j.pharma.2014.05.001. Epub 2014 Jul 5. Review. French.

PMID:
25438654
15.

Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: a 2013 follow-up study.

Berruyer M, Tanguay C, Caron NJ, Lefebvre M, Bussières JF.

J Occup Environ Hyg. 2015;12(2):87-94. doi: 10.1080/15459624.2014.949725.

PMID:
25105559
16.
17.

Paediatric clinical research from the perspective of hospital pharmacists from France and Canada.

Guérin A, Tanguay C, Lebel D, Prot-Labarthe S, Bourdon O, Bussières JF.

Int J Pharm Pract. 2014 Dec;22(6):415-23. doi: 10.1111/ijpp.12099. Epub 2014 Mar 6.

PMID:
24602206
18.

Environmental contamination with methotrexate in Canadian community pharmacies.

Merger D, Tanguay C, Langlois É, Lefebvre M, Bussières JF.

J Am Pharm Assoc (2003). 2013 Jul-Aug;53(4):423-6. doi: 10.1331/JAPhA.2013.12245.

PMID:
23892817
19.

Multicenter study of environmental contamination with antineoplastic drugs in 33 Canadian hospitals.

Merger D, Tanguay C, Langlois E, Lefebvre M, Bussières JF.

Int Arch Occup Environ Health. 2014 Apr;87(3):307-13. doi: 10.1007/s00420-013-0862-0. Epub 2013 Mar 8.

PMID:
23471647
20.

Le paradis des listes de vérification : le réseau EQUATOR.

Tanguay C, Lebel D, Bussières JF.

Can J Hosp Pharm. 2013 Jan;66(1):43-4. French. No abstract available.

21.

Interplay between type 1A topoisomerases and gyrase in chromosome segregation in Escherichia coli.

Usongo V, Tanguay C, Nolent F, Bessong JE, Drolet M.

J Bacteriol. 2013 Apr;195(8):1758-68. doi: 10.1128/JB.02001-12. Epub 2013 Feb 8.

22.

Création d'une grille d'autoévaluation du soutien pharmaceutique aux essais cliniques.

Guérin A, Tanguay C, Lebel D, Bussières JF.

Can J Hosp Pharm. 2012 Nov;65(6):450-7. French. No abstract available.

23.

Environmental contamination with hazardous drugs in quebec hospitals.

Bussières JF, Tanguay C, Touzin K, Langlois E, Lefebvre M.

Can J Hosp Pharm. 2012 Nov;65(6):428-35.

24.

Prioritizing pharmaceutical activities: a simulation by pharmacy residents.

Renet S, Tanguay C, Hall K, Bussières JF.

J Pharm Pract. 2013 Aug;26(4):367-75. doi: 10.1177/0897190012465952. Epub 2012 Nov 26.

PMID:
23184408
25.

Perspectives sur les possibilités de publications pharmaceutiques au Canada.

Hébert G, Tremblay MÉ, Tanguay C, Bussières JF.

Can J Hosp Pharm. 2012 May;65(3):234-5. French. No abstract available.

26.

Prioritizing pharmaceutical activities: a simulation exercise.

Renet S, Rochais E, Tanguay C, Hall KW, Bussières JF.

Can J Hosp Pharm. 2012 Mar;65(2):119-24. No abstract available.

27.

[Prioritization of healthcare programs by pharmacy students from France and from Quebec, according to the perceived impact of a decentralized pharmacist].

Renet S, Rochais É, Bussières JF, Lebel D, Tanguay C, Bourdon O.

Ann Pharm Fr. 2012 Mar;70(2):94-103. doi: 10.1016/j.pharma.2012.01.001. Epub 2012 Feb 15. French.

PMID:
22500961
28.

Depletion of RNase HI activity in Escherichia coli lacking DNA topoisomerase I leads to defects in DNA supercoiling and segregation.

Usongo V, Nolent F, Sanscartier P, Tanguay C, Broccoli S, Baaklini I, Drlica K, Drolet M.

Mol Microbiol. 2008 Aug;69(4):968-81. doi: 10.1111/j.1365-2958.2008.06334.x. Epub 2008 Jun 28.

29.
30.

Vaginal radical trachelectomy in the treatment of cervical cancer: the role of frozen section.

Tanguay C, Plante M, Renaud MC, Roy M, Têtu B.

Int J Gynecol Pathol. 2004 Apr;23(2):170-5.

PMID:
15084846
31.

Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases.

Tanguay C, Harvey I, Houde M, Srigley JR, Têtu B.

Mod Pathol. 2003 May;16(5):512-4.

32.

[Urinary incontinence and long-term care].

Lutumba Ntetu A, St-Laurent L, Tanguay C.

Can Nurse. 1995 Mar;91(3):46-9. French.

PMID:
7704884
33.

[Survey on the usage of psychodysleptics (hallucinogens) in the colleges and universities of the province of Quebec. II. Methodology and preliminary results].

Radouco-Thomas S, Villeneuve A, Hudon M, Tanguay C, Monnier D, Gendron C, Radouco-Thomas C.

Laval Med. 1969 Jan;40(1):103-7. French. No abstract available.

PMID:
5774361
34.

[Survey on the use of psychodysleptics (hallucinogens) in the collages and universities of the Province of Quebec. I. Questionnaire used].

Radouco-Thomas S, Villeneuve A, Hudon M, Monnier M, Tanguay C, Tessier L, Lajeunesse N, Gendron C, Radouco-Thomas C.

Laval Med. 1968 Nov;39(9):817-33. French. No abstract available.

PMID:
5748241

Supplemental Content

Loading ...
Support Center